Abstract
Matrix metalloproteinases expression is used as biomarker for various cancers and associated malignancies. Since these proteinases can cleave many intracellular proteins, overexpression tends to be toxic; hence, a challenge to purify them. To overcome these limitations, we designed a protocol where full length pro-MMP2 enzyme was overexpressed in E. coli as inclusion bodies and purified using 6xHis affinity chromatography under denaturing conditions. In one step, the enzyme was purified and refolded directly on the affinity matrix under redox conditions to obtain a bioactive protein. The pro-MMP2 protein was characterized by mass spectrometry, CD spectroscopy, zymography and activity analysis using a simple in-house developed ‘form invariant’ assay, which reports the total MMP2 activity independent of its various forms. The methodology yielded higher yields of bioactive protein compared to other strategies reported till date, and we anticipate that using the protocol, other toxic proteins can also be overexpressed and purified from E. coli and subsequently refolded into active form using a one step renaturation protocol.
Similar content being viewed by others
References
Hrabec, E., Naduk, J., Strek, M., & Hrabec, Z. (2007). Type IV collagenases (MMP-2 and MMP-9) and their substrates–intracellular proteins, hormones, cytokines, chemokines and their receptors. Postepy Biochemii, 53, 37–45.
Shimokawa Ki, K., Katayama, M., Matsuda, Y., Takahashi, H., Hara, I., Sato, H., et al. (2002). Matrix metalloproteinase (MMP)-2 and MMP-9 activities in human seminal plasma. Molecular Human Reproduction, 8, 32–36.
Nissinen, L., & Kahari, V. M. (2014). Matrix metalloproteinases in inflammation. Biochimica et Biophysica Acta, 1840, 2571–2580.
Cauwe, B., Van den Steen, P. E., & Opdenakker, G. (2007). The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Critical Reviews in Biochemistry and Molecular Biology, 42, 113–185.
Hadler-Olsen, E., Winberg, J. O., & Uhlin-Hansen, L. (2013). Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biology, 34, 2041–2051.
Dufour, A., & Overall, C. M. (2013). Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends in Pharmacological Sciences, 34, 233–242.
Hua, H., Li, M., Luo, T., Yin, Y., & Jiang, Y. (2011). Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cellular and Molecular Life Sciences, 68, 3853–3868.
Koo, B. H., Kim, Y. H., Han, J. H., & Kim, D. S. (2012). Dimerization of matrix metalloproteinase-2 (MMP-2): functional implication in MMP-2 activation. Journal of Biological Chemistry, 287, 22643–22653.
Ra, H. J., & Parks, W. C. (2007). Control of matrix metalloproteinase catalytic activity. Matrix Biology, 26, 587–596.
Windsor, L. J., & Steele, D. L. (2001). Expression of recombinant matrix metalloproteinases in Escherichia coli. Methods in Molecular Biology, 151, 191–205.
Windsor, L. J., & Steele, D. L. (2010). Expression of recombinant matrix metalloproteinases in Escherichia coli. Methods in Molecular Biology, 622, 67–81.
Massova, I., Kotra, L. P., Fridman, R., & Mobashery, S. (1998). Matrix metalloproteinases: structures, evolution, and diversification. The FASEB Journal, 12, 1075–1095.
Nagase, H., Visse, R., & Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, 69, 562–573.
Brew, K., & Nagase, H. (2010). The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochimica et Biophysica Acta, 1803, 55–71.
Steffensen, B., Hakkinen, L., & Larjava, H. (2001). Proteolytic events of wound-healing–coordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules. Critical Reviews in Oral Biology and Medicine, 12, 373–398.
Martignetti, J. A., Aqeel, A. A., Sewairi, W. A., Boumah, C. E., Kambouris, M., Mayouf, S. A., et al. (2001). Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nature Genetics, 28, 261–265.
Monaco, S., Gioia, M., Rodriguez, J., Fasciglione, G. F., Di Pierro, D., Lupidi, G., et al. (2007). Modulation of the proteolytic activity of matrix metalloproteinase-2 (gelatinase A) on fibrinogen. Biochemical Journal, 402, 503–513.
Springman, E. B., Angleton, E. L., Birkedal-Hansen, H., & Van Wart, H. E. (1990). Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a “cysteine switch” mechanism for activation. Proceedings of the National Academy Sciences, 87, 364–368.
Van Wart, H. E., & Birkedal-Hansen, H. (1990). The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proceedings of the National Academy Sciences, 87, 5578–5582.
Kupai, K., Szucs, G., Cseh, S., Hajdu, I., Csonka, C., Csont, T., et al. (2010). Matrix metalloproteinase activity assays: Importance of zymography. Journal of Pharmacological and Toxicological Methods, 61, 205–209.
Hu, X., & Beeton, C. (2010). Detection of functional matrix metalloproteinases by zymography. Journal of visualized experiments. doi:10.3791/2445.
Rabilloud, T., Vuillard, L., Gilly, C., & Lawrence, J. J. (1994). Silver-staining of proteins in polyacrylamide gels: a general overview. Cellular and Molecular Biology, 40, 57–75.
Turk, B. E., Huang, L. L., Piro, E. T., & Cantley, L. C. (2001). Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnology, 19, 661–667.
Saini, D. K., Pant, N., Das, T. K., & Tyagi, J. S. (2002). Cloning, overexpression, purification, and matrix-assisted refolding of DevS (Rv 3132c) histidine protein kinase of mycobacterium tuberculosis. Protein Expression and Purification, 25, 203–208.
Vallejo, L. F., & Rinas, U. (2004). Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins. Microbial Cell Factories, 3, 11.
Deleage, G., & Geourjon, C. (1993). An interactive graphic program for calculating the secondary structure content of proteins from circular dichroism spectrum. Computer Applications in the Biosciences, 9, 197–199.
Sariahmetoglu, M., Crawford, B. D., Leon, H., Sawicka, J., Li, L., Ballermann, B. J., et al. (2007). Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. The FASEB Journal, 21, 2486–2495.
Goncalves, A. N., Meschiari, C. A., Stetler-Stevenson, W. G., Nonato, M. C., Alves, C. P., Espreafico, E. M., et al. (2012). Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli. Journal of Biotechnology, 157, 20–24.
Ikeda, M., Maekawa, R., Tanaka, H., Matsumoto, M., Takeda, Y., Tamura, Y., et al. (2000). Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clinical Cancer Research, 6, 3290–3296.
Murnane, M. J., Cai, J., Shuja, S., McAneny, D., Klepeis, V., & Willett, J. B. (2009). Active MMP-2 effectively identifies the presence of colorectal cancer. International Journal of Cancer, 125, 2893–2902.
Rossello, A., Nuti, E., Orlandini, E., Carelli, P., Rapposelli, S., Macchia, M., et al. (2004). New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorganic Medicine Chemistry, 12, 2441–2450.
Baker, A. H., Edwards, D. R., & Murphy, G. (2002). Metalloproteinase inhibitors: biological actions and therapeutic opportunities. Journal of Cell Science, 115, 3719–3727.
Morrison, C. J., Butler, G. S., Bigg, H. F., Roberts, C. R., Soloway, P. D., & Overall, C. M. (2001). Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. Journal of Biological Chemistry, 276, 47402–47410.
Itoh, Y., Binner, S., & Nagase, H. (1995). Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochemical Journal, 308(Pt 2), 645–651.
Ye, Q. Z., Johnson, L. L., Yu, A. E., & Hupe, D. (1995). Reconstructed 19kDa catalytic domain of gelatinase A is an active proteinase. Biochemistry, 34, 4702–4708.
Cheng, D., Shen, Q., Nan, F., Qian, Z., & Ye, Q. Z. (2003). Purification and characterization of catalytic domains of gelatinase A with or without fibronectin insert for high-throughput inhibitor screening. Protein Expression and Purification, 27, 63–74.
Nagase, H., Fields, C. G., & Fields, G. B. (1994). Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). Journal of Biological Chemistry, 269, 20952–20957.
Monaco, S., Sparano, V., Gioia, M., Sbardella, D., Di Pierro, D., Marini, S., et al. (2006). Enzymatic processing of collagen IV by MMP-2 (gelatinase A) affects neutrophil migration and it is modulated by extracatalytic domains. Protein Science, 15, 2805–2815.
Acknowledgments
Financial assistance to DKS from Department of Science and Technology (DST); Junior Research Fellowship to RJ from UGC; Assistance from proteomics facility, IISc for mass spectrometry and Gajendra, Department of Biochemistry, IISc for CD spectroscopy is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Additional information
Krishna Kumar Singh, Ruchi Jain, Harini Ramanan have contributed equally to this work.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Singh, K.K., Jain, R., Ramanan, H. et al. Matrix-Assisted Refolding, Purification and Activity Assessment Using a ‘Form Invariant’ Assay for Matrix Metalloproteinase 2 (MMP2). Mol Biotechnol 56, 1121–1132 (2014). https://doi.org/10.1007/s12033-014-9792-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12033-014-9792-7